Corteria Pharmaceuticals

Corteria Pharmaceuticals is a spin-out company from Sanofi. The company is focused on the development of novel therapies for heart failure subpopulations: a first-in-class CRF2 peptide agonist for outpatient worsening heart failure (OWHF) and a first-in-class vasopressin neutralizing antibody for the treatment of acute heart failure with hyponatremia (AHF).

  • CEO and Cofounder: Philip Janiak
  • CSO and Cofounder: Marie-Laure Ozoux
  • Location: París
  • Website: